Business
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women’s Health Week. Conference Call and Webcast Today at 4:30 p.m. ET “We are hosting our financial results and business update call from New York, in the middle of National Women’s Health Week,” said Sabrina Martucci Johns
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":114,"url":"https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/d0Q6BxIcwkh3NEWtzlz17g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MA--/https://media.zenfs.com/en/globenewswire.com/b3330a5ea5a04281ef6459cd3df6a853","width":300,"height":114}},"lazy":false},{"type":"text","content":"Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women’s Health Week.","length":296,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast Today at 4:30 p.m. ET","length":49,"tagName":"p"},{"type":"text","content":"“We are hosting our financial results and business update call from New York, in the middle of National Women’s Health Week,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. “Daré was built on the conviction that women’s health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribbon in a press release. A category worth building, funding, and holding accountable for delivering to women the healthcare options they deserve. This week alone, we announced a second consecutive positive DSMB review of interim data from our ongoing Phase 3 clinical trial of Ovaprene – two consecutive positive reviews of interim data for a product candidate that could be the first FDA-approved, hormone-free, monthly contraceptive. And with the planned commencement of DARE to PLAY dispensing and the anticipated commercial launch of Flora Sync LF5, summer 2026 is expected to mark the first time Daré Bioscience records direct product revenue. We built this company to change how women experience healthcare. We believe that change is beginning in earnest now.”","length":1115,"tagName":"p"},{"type":"tex...